Core Viewpoint - Madrigal Pharmaceuticals, Inc. is set to release its fourth-quarter and full-year 2025 financial results on February 19, 2026, prior to the opening of U.S. financial markets [1] Company Overview - Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs [3] - The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist aimed at addressing key underlying causes of MASH [3] - Rezdiffra is the first and only medication approved by both the FDA and European Commission for treating MASH with moderate to advanced fibrosis (F2 to F3) [3] - An ongoing Phase 3 outcomes trial is currently evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c) [3]

Core Viewpoint - MindBio Therapeutics Corp. is advancing its AI-driven technology for drug and alcohol intoxication detection, aiming to disrupt traditional testing methods in the mining industry, particularly in South America [1][6]. Group 1: Technology and Applications - The company has developed a world-first AI prediction tool that analyzes voice to detect intoxication from substances like alcohol, hallucinogens, and plans to expand to other drugs [1][5]. - The technology is being positioned as an enterprise solution for the mining industry, where it can serve as a first-line screening method for multiple substances at entry points [2][3]. - Current drug and alcohol testing methods in the mining sector are slow, expensive, and invasive, often requiring bodily fluid samples, which the company's technology aims to replace with a non-invasive voice analysis [3][5]. Group 2: Market Opportunity and Industry Context - In Chile, over 75% of mining workers consume alcohol, with more than 40% identified as problem drinkers, and 9% using drugs, highlighting a significant market need for effective screening solutions [4]. - Internationally, 20-25% of occupational accidents are linked to substance use, indicating a substantial opportunity for MindBio's technology to reduce workplace incidents and associated costs [4]. - The CEO expressed optimism about the commercial interest from the mining industry, viewing it as a massive opportunity to transform drug and alcohol testing processes globally [6][7].

BUFFALO, N.Y.--(BUSINESS WIRE)---- $ROCK #ROCK--Gibraltar Industries, Inc. (Nasdaq: ROCK), a leading manufacturer and provider of products and services for the residential, agtech, and infrastructure markets, today announced that it has closed its acquisition of OmniMax International ("OmniMax") from funds managed by Strategic Value Partners, LLC and its affiliates following receipt of all required regulatory approvals and satisfaction of customary closing conditions. The all-cash transaction was valued at ...

Adagio Medical to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceFeb 2, 2026 8:05 AM Eastern Standard Time# Adagio Medical to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceShare---LAGUNA HILLS, Calif.--([BUSINESS WIRE])--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio†or "the Company†), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today a ...

LAKE MARY, Fla.--(BUSINESS WIRE)--VerifyMe, Inc. (Nasdaq: VRME) ("VerifyMe†, "The Company†) today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq†) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq confirmed that for the last 10 consecutive business days, from January 13, 2026 through January 29, 2026, the closing bid price of the Company ...

Core Insights - N2OFF, Inc. is focusing on drug discovery and solar energy investments, highlighting a peer-reviewed study on mitochondrial carriers as potential biomarkers for spaceflight-induced dysfunctions [1][2][4] Group 1: Study Overview - The study titled "SLC25A mitochondrial carriers as biomarkers and therapeutic targets of spaceflight-induced dysfunction" was published on December 30, 2025, and examines the expression of 53 SLC25A genes under microgravity conditions [2][3] - The analysis found differential regulation of SLC25A carriers, suggesting their potential as biomarkers for mitochondrial dysfunction [3] Group 2: Company Focus - MitoCareX Bio, a subsidiary of N2OFF, is developing small-molecule drugs targeting mitochondrial carriers, which are crucial for cellular energy metabolism and are involved in various diseases [4][6] - The company utilizes proprietary methods, including the MITOLINE algorithm, to model and validate drug targets within the SLC25A family [4] Group 3: Investment Strategy - N2OFF is also investing in European renewable energy assets, specifically solar projects, under a Ready to Build (RTB) business model [6] - The company is the lead investor in four solar projects across three EU countries, introduced by its subsidiary Solterra Renewable Energy Ltd [6]

Amber Beverage Group has initiated legal protection for its Latvian operations as it faces cash flow pressures caused by “external challenges”. In a filing to the Nasdaq Baltic stock exchange on Friday (30 January), the company said Amber Latvijas balzams will continue to operate as normal while it “works with creditors to establish a sustainable financial structure”. Normunds Staņēvičs, the CEO of ABG, called the decision “difficult but necessary”. “The legal protection process gives us the legal safe ...

Core Viewpoint - Nvidia's ambitious plan to invest up to $100 billion in OpenAI has encountered internal doubts and is currently being reassessed, potentially leading to a significantly smaller investment [2][3][5]. Group 1: Investment Details - Nvidia had initially announced plans to invest up to $100 billion in OpenAI to strengthen their partnership and support OpenAI's data center expansion [2]. - Current discussions are focusing on a smaller equity investment, potentially in the tens of billions of dollars, as part of OpenAI's ongoing fundraising efforts [3]. Group 2: Internal Concerns - Nvidia executives have raised concerns regarding the scope and structure of the proposed deal, leading to a reevaluation of the partnership [2]. - CEO Jensen Huang indicated that the original $100 billion proposal was nonbinding and never finalized, expressing caution about the investment [5]. Group 3: Competitive Landscape - Huang has voiced concerns about OpenAI's financial discipline, particularly regarding its aggressive spending to scale infrastructure [6]. - OpenAI faces increasing competition from major players like Alphabet's Google and Amazon-backed Anthropic, which may influence Nvidia's investment decision [7]. Group 4: Market Interest - OpenAI is reportedly seeking to raise up to $100 billion at a valuation of approximately $830 billion, attracting interest from major tech firms and investors [8]. - Amazon is also in discussions to invest tens of billions in OpenAI, with potential figures reaching $50 billion [9].

Core Viewpoint - Microsoft shares experienced a significant decline of over 12% following disappointing quarterly earnings, resulting in a loss of $357 billion in market value, marking the worst day since the 2020 stock market crash [1][2] Financial Performance - Microsoft is now in a bear market, down nearly 21% from its all-time high, raising questions among investors about whether this decline presents a buying opportunity or if it is prudent to wait [2] - Azure revenue grew by 39%, which, while still strong compared to competitors, fell short of expectations as it was 1% below the previous quarter [6][7] Investment Sentiment - The steep drop in stock price has led to a perception that Microsoft is misunderstood, with investors reacting harshly to heavy AI capital expenditures without sufficient quarter-over-quarter growth [4][5] - There is a growing concern that the significant increase in capital expenditures, which rose 66% year-over-year to $37.5 billion, has not yet translated into expected growth, leading to a negative outlook for the recent quarter [8][6] Future Outlook - CFO Amy Hood indicated that demand for AI services is exceeding supply, suggesting that capacity constraints are currently limiting growth potential, rather than a lack of demand [9][10] - Once Microsoft addresses its capacity issues, there is potential for Azure to regain its status as a key growth driver for the company [10]

Sierra Bancorp Reports Record Quarterly Earnings and 2025 ResultsFeb 2, 2026 8:01 AM Eastern Standard Time# Sierra Bancorp Reports Record Quarterly Earnings and 2025 ResultsShare---PORTERVILLE, Calif.--([BUSINESS WIRE])--Sierra Bancorp (Nasdaq: BSRR), parent of Bank of the Sierra, today announced unaudited financial results for the three-and twelve-month periods ended December 31, 2025. Sierra Bancorp reported consolidated net income in the fourth quarter of 2025 of $12.9 million, or $0.97 per diluted share ...